ClariVest Asset Management LLC purchased a new stake in shares of Inogen Inc (NASDAQ:INGN) during the third quarter, HoldingsChannel.com reports. The fund purchased 4,496 shares of the medical technology company’s stock, valued at approximately $1,097,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INGN. Catalyst Capital Advisors LLC bought a new position in shares of Inogen during the second quarter valued at about $112,000. Harvest Fund Management Co. Ltd purchased a new stake in Inogen during the third quarter worth about $128,000. Advisory Services Network LLC increased its holdings in Inogen by 162.5% during the third quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock worth $128,000 after buying an additional 325 shares during the last quarter. First Quadrant L P CA purchased a new stake in Inogen during the third quarter worth about $134,000. Finally, Flagship Harbor Advisors LLC increased its holdings in Inogen by 1,090.9% during the third quarter. Flagship Harbor Advisors LLC now owns 655 shares of the medical technology company’s stock worth $157,000 after buying an additional 600 shares during the last quarter. 96.94% of the stock is currently owned by institutional investors.

A number of research firms recently issued reports on INGN. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 7th. Zacks Investment Research downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, September 5th. Stifel Nicolaus set a $258.00 price objective on shares of Inogen and gave the stock a “buy” rating in a report on Tuesday, August 21st. Piper Jaffray Companies raised their price objective on shares of Inogen to $245.00 and gave the stock an “overweight” rating in a report on Tuesday, August 7th. Finally, Needham & Company LLC downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating and raised their price objective for the stock from $254.00 to $296.00 in a report on Monday, September 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and a consensus price target of $244.67.

NASDAQ INGN opened at $138.09 on Thursday. Inogen Inc has a 52-week low of $112.78 and a 52-week high of $287.79. The stock has a market cap of $3.02 billion, a P/E ratio of 65.24, a P/E/G ratio of 2.75 and a beta of 1.56.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.21. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The business had revenue of $95.29 million during the quarter, compared to the consensus estimate of $90.94 million. During the same quarter last year, the company posted $0.33 earnings per share. The firm’s quarterly revenue was up 38.0% compared to the same quarter last year. As a group, analysts forecast that Inogen Inc will post 2.1 EPS for the current fiscal year.

In other news, Director Raymond Huggenberger sold 10,500 shares of Inogen stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $282.57, for a total value of $2,966,985.00. Following the completion of the transaction, the director now owns 8,797 shares in the company, valued at $2,485,768.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Heath Lukatch sold 500 shares of Inogen stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $261.54, for a total transaction of $130,770.00. Following the completion of the transaction, the director now owns 4,239 shares of the company’s stock, valued at approximately $1,108,668.06. The disclosure for this sale can be found here. Insiders sold 37,500 shares of company stock valued at $9,008,475 in the last quarter. Corporate insiders own 5.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ClariVest Asset Management LLC Takes $1.10 Million Position in Inogen Inc (INGN)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/11/22/clarivest-asset-management-llc-takes-1-10-million-position-in-inogen-inc-ingn.html.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: Yield Curve

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.